Publications
Schneider, E.L. et al. Long-Acting, Longer-Acting, and Ultralong-Acting Antiobesity Peptides. J. Med. Chem 68: 2301-2306. (2025)
Hou, X. et al. Antitumor activity of rucaparib plus PLX038A in serious endometrial carcinoma. J Exp Clin Cancer Res 44:150. (2025)
Santi, D.V. When Can Weekly Anti-Obesity Peptides Be Used For Monthly Administration? Diabetes Obes Metab, 27: 1628-1629. (2025)
Meher, N. et al. PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogenous Enhanced Permeability and Retention in Prostate Cancer. Mol Cancer Thera 24: 141-151. (2025)
Hoshi, S., et al. Intravitreal Injection of Dorzolamide-Loaded Polyethylene Glycol Microsphere Produces Sustained Lowering of Intraocular Pressure in Rabbits. Invest. Ophthalmol. Vis. Sci., 65(7):3965. (2024)
Schneider, E.L. et al. The Limitation of Lipidation: Conversion of Semaglutide From Once-Weekly to Once-Monthly Dosing. PNAS, 121(47): doi.org/10.1073/pnas.2415815121 (2024)
Hangasky, J.A. et al. Leveraging Long-Acting IL-15 Agonists for Intratumoral Delivery and Enhanced Antimetastatic Activity. Front Immunol, 15:1458145. doi: 10.3389/fimmu.2024.1458145 (2024)
Jung, J. et al. PLX 038A, a Long-Acting SN-38, Penetrates The Blood-Tumor-Brain-Barrier, Accumulates and Releases SN-38 In Brain Tumors To Increase Survival Of Tumor Bearing Mice. Sci Reports 14:14175. doi.org/10.1038/s41598-024-64186-2. (2024)
Mironova, E. et al. Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors. Cancers, 16, 2041. doi.org/10.3390/cancers16112041. (2024)
Henise, J. et al. A Platform Technology for Ultra-Long Acting Intratumoral Therapy. Sci Reports 14:14000. doi:org/10.1038/s41598-024-64261-8. (2024)
Carreras, C. et al. Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans. Bioconjugate Chem 35(4), 551-558. (2024)
Santi, D.V. et al. Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors? BioDrugs, doi.org/10.1007/s40259-024-00643-8. (2024)
Meher, N. et al. Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer. Adv Healthcare Mater 2304618, doi: 10.1002/adhm.202304618. (2024)
Fontaine, S. et al. A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors. Cancer Res Commun, 3(5): https://doi.org/10.1158/2767-9764.CRC-22-0517 (2023)
Penas-Prado, M. et al. Improving clinical trial access for people with rare CNS tumors: a phase I/II trial of PLX038 in tumors with MYC-C or MYC-N amplifications incorporating correlative studies and patient reported outcomes (PRO) - An NCI-CONNECT Clinical Trial. 27th Annual Meeting and Education Day of the Society for Neuro-Oncology, November 16-20, 2022.
Meher, N. et al. Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers. Appl Mater Interfaces 14: 50569-50582. (2022)
Del Pozo, V. et al. PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma. iScience, 25, 1-15. (2022)
Thomas, A. et al. PLX038: A Long-Acting Topoisomerase 1 Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors. Mol Cancer Thera, 21(11), 1722-1728. (2022)
Schneider, E. et al. A long-acting C-natriuretic peptide for achondroplasia. PNAS, 119(30), e2201067119. doi.org/10.1073/pnas.2201067119. (2022)
Hangasky, J.A. et al. A very long-acting IL-15: implications for the immunotherapy of cancer. J Immunother Cancer, 10, e004104. doi:10.1136/jitc-2021-004104. (2022)
Hearn, B. et al. Attenuation of the Reaction of Michael Acceptors with Biologically Important Nucleophiles. Bioconjugate Chem. 32, 794-800. (2021)
Santi, D. et al. Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? Annals of Translational Medicine, 9(14):1113. https://dx.doi.org/10.21037/atm-21-1103. (2021)
Henise, J. et al. Facile preparation of tetra-polyethylene glycol hydrogel microspheres for drug delivery by cross-flow membrane emulsification. Engineering Reports, e12412. https://doi.org/10.1002/eng2.12412. (2021)
Fontaine, S. et al. A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. Cancer Research, 81(4), 1076-1086. (2021)
Hangasky, J.A. et al. Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink. Frontiers in Immunology, 11(1813). doi: 10.3389/fimmu.2020.01813. (2020)
Henise, J. et al. High-throughput, aseptic production of injectable Tetra-PEG hydrogel microspheres for delivery of releasable covalently bound drugs + SI. Engineering Reports, https://onlinelibrary.wiley.com/doi/full/10.1002/eng2.12213. (2020)
Guilu, S. et al. Prospective use of the single-mouse experimental design for the evaluation of PLX038A. Cancer Chemotherapy and Pharmacology, 85, 251-263. (2020)
Schneider, E. et al. A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. Domestic Animal Endocrinology, Vol 70, 106373. (2020)
Henise, J. et al. Autoclave sterilization of tetra-polyethylene glycol hydrogel biomaterials with b-elimination crosslinks. Engineering Reports, https://doi.org/10.1002/eng2.12091 (2019)
Beckford Vera, D. et al. PET imaging of the EPR effect in tumor xenografts using small 15 nm diameter polyethylene glycols labeled with zirconium-89. Molecular Cancer Therapeutics, DOI: 10.1158/1535-7163.MCT-19-0709. (2019)
Fontaine, S. et al. PLX038: a PEGylated prodrug of SN-38 independence of UGT1A1 activity. Cancer Chemotherapy and Pharmacology, https://doi.org/10.1007/s00280-019-03987-z. (2019)
Fontaine, S. et al. Species-specific optimization of PEG~SN~38 prodrug pharmacokinetics and antitumor effects in triple-negative BRCA1-deficient xenograft. Cancer Chemotherapy and Pharmacology, https://doi.org/10.1007/s00280-019-03903-5. (2019)
Henise, J. et al. In Vitro-In Vivo Correlation for the Degradation of Tetra-PEG Hydrogel Microspheres with Tunable β-Eliminative Crosslink Cleavage Rates. International Journal of Polymer Science, Vol. 2019, Article ID 9483127. (2019)
Fontaine, S. et al. PLX038: A long-acting prodrug of SN-38 and enhancer of the DNA Damage Response. Gordon Conference. (2018).
Machinaga, N. et al. A Controlled Release System for Long-Acting Intravitreal Delivery of Small Molecules. TVST, Vol. 7, No. 4, Article 21. (2018)
Hearn, B. et al. Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system. Journal of Controlled Release, 278, 74-79. (2018)
Schneider, E. et al. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP 1 Receptor Agonist. ACS Chemical Biology, 12, 2107-2116. (2017)
Schneider, E. et al. Approach For Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake. Bioconjugate Chemistry, 27, 2534-2539. (2016)
Henise, J. et al. Surgical Sealants with Tunable Swelling, Burst Pressures, and Biodegradation Rates. Journal of Biomedical Materials Research B, 1058(6), 1602-1611. (2016)
Cerchiari, A.E. et al. Probing the Luminal Microenvironment of Reconstituted Epithelial Microtissues. Scientific Reports, 6,33148; doi: 10.1038/srep33148. (2016)
Schneider, E. et al. Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugated Provide Very Long-Acting Octreotide. Bioconjugate Chemistry, 27, 1638-1644. (2016)
Schneider, E. et al. Hydrogel Drug Delivery System Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide. Bioconjugate Chemistry, 27, 1210-1215. (2016)
Reid, R. et al. Analytical and Simulation-Based Models for Drug Release and Gel-Degradation in a Tetra-PEG Hydrogel Drug-Delivery System. Macromolecules, 2015, 48, 7359-7369. (2015)
Schneider, E. et al. Half-Life Extension of the HIV-Fusion Inhibitor Peptide TRI-1144 Using a Novel Linker Technology. European Journal of Pharmaceuticals and Biopharmaceutics, 93, 254-259. (2015)
Henise, J. et al. Biodegradable Tetra-PEG Hydrogels as Carriers for a Releasable Drug Delivery System. Bioconjugate Chem, 26, 270-278. (2015)
Fontaine, S. et al. Long-Term Stabilization of Maleimide−Thiol Conjugates. Bioconjugate Chem., 26, 145-152. (2015)
Lawrence, M. et al. The Intravitreal Pharmacokinetics of Fluorophores Conjugated to PEGs by Non-Cleavable and Self-Cleaving Linkers in Non-human Primates. ARVO 2014 Annual Meeting. (2014)
Santi, D.V. et al. Macromolecular Prodrug that provides the Irinotecan Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax, and Low Glucuronide Formation. J.MedChem., 57, 2303-2314. (2014)
Schneider, E. et al. Beta-Eliminative Releasable Linkers Adapted for Bioconjugation of Macromolecules to Phenols. Bioconjugate Chem., 24, 1990-1997. (2013)
Henise, J. et al. An optimized hydrogel offers tunable half-life extension of peptides and proteins. Peptide Conference 2013.
Schneider, E.L., et al. Self-administered long-acting octreotide conjugates. Peptide Conference 2013.
Ashley, G.W. et al. Hydrogel drug delivery system with predictable and tunable drug release and degradation rates. PNAS, 110(6), 2318-2323. (2013)
Schneider, E.L. et al. Predictable half-life extension demonstrated through peptide TRI-1144. Peptide Conference 2012.
Henise, J. et al. A biodegradable hydrogel drug delivery system for tunable half-life extension. Peptide Conference 2012.
Santi, D.V. et al. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. PNAS, 109(16), 6211-6216. (2011)
Schneider, E. et al. Predictable and tunable drug release from macro-molecular conjugates. Peptide Conference 2011.
